Depression Research
Major depressive disorder, often referred to as major depression, is a heterogenous condition with complex and diverse neurobiological etiologies. Depression is characterized by a triad of symptoms: low or depressed mood, anhedonia and low energy or fatigue. Approximately 15% of the population in developed countries has been affected by depression in their lifetime and the chance of developing depression is twice as high in women. 40-50% of depressive causes are inheritable (genes as yet unidentified) and the remaining 50-60% of causes are caused by environmental stressors.
Depression Research Products Targets
- FGFR (5)
- Voltage-gated Calcium Channel (CaV) (38)
- Others (13)
- Glucocorticoid Receptor (9)
- Nucleoside Transporter (5)
- Glycine Transporter (6)
- GABA (10)
- Cannabinoid Transporter (10)
- Acetylcholine Transporter (1)
- D4 Receptor (12)
- 5-HT7 Receptor (11)
- 5-HT6 Receptor (14)
- 5-ht5 Receptor (2)
- 5-HT4 Receptor (17)
- NK2 Receptor (7)
- NK1 Receptor (15)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- AMPA Receptor (45)
- D3 Receptor (12)
- NK3 Receptor (5)
- Vesicular Monoamine Transporter (4)
- NMDA Receptor (87)
- Kainate Receptor (22)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Trk Receptor (13)
- Trace Amine 1 Receptor (2)
- Glutamate Transporter (18)
- Dopamine Transporter (20)
- CRF2 Receptor (3)
- CRF1 Receptor (5)
- Adrenergic Transporter (23)
- 5-HT Transporter (30)
- Vasopressin Receptor (6)
- Monoamine Oxidase (10)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β3 Receptor (12)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
Products for Depression Research - Page 44
- Cat.No. Product Name Information/Activity
-
BCC6896
CPCCOEt
179067-99-3
-
BCC6888
E4CPG
E4CPG is a novel group I/group II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG .
-
BCC7345
Fenobam
Fenobam is a selective, orally active, and non-competitive mGluR5 antagonist acting at an allosteric modulatory site (Kd values are 54 and 31 nM for rat and human recombinant mGlu5 receptors, respectively). Fenobam displays inverse agonist activity which blocks the mGlu5 receptor basal activity with an IC50 of 84 nM. Fenobam exerts anxiolytic activity.
-
BCC7166
HexylHIBO
334887-43-3
-
BCC7167
(S)-HexylHIBO
334887-48-8
-
BCC7332
JNJ 16259685
JNJ16259685 is a selective antagonist of mGlu1 receptor, and inhibits the synaptic activation of mGlu1 in a concentration-dependent manner with IC50 of 19 nM.
-
BCC6983
LY 367385
LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 has an IC50 of 8.8 μM for inhibits of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with > 100 μM for mGlu5a. LY367385 has neuroprotective, anticonvulsant and antiepileptic effects.
-
BCC7347
LY 456236 hydrochloride
338736-46-2
-
BCC7281
3-MATIDA
518357-51-2
-
BCC7756
(RS)-MCPG disodium salt
1303994-09-3


